Stay updated with breaking news from Mandatory non. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hyrimoz approved for use in all same indications as reference medicine including rheumatology, gastroenterology and dermatology. Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. BOUCHERVILLE, Quebec, Dec. 17, 2020 (GLOBE NEWSWIRE) Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®) on November 4, 2020 for marketing in Canada. Hyrimoz ® has been approved for the treatment of the same nine (9) life-threatening or serious debilitating conditions in adults and children as the reference medicine , including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis. ....